HealthQuill Wellcome Trust
The UK and Wellcome Trust will invest Ā£600 million to create a new health data research service to accelerate the discovery of life-saving drugs, improve patient care and make Britain ā€œthe best place in the worldā€ for medical research.
Drugs Health Pharma

UK, Wellcome to build Ā£600m health data service, fast-pace clinical trials

HQ Team May 19, 2025: The UK and Wellcome Trust will invest Ā£600 million to create a new health data research service to.

Read More
Antibiotic-resistant infections may kill 39.1 million people in the next 25 years equating to three deaths a minute, a global study finds.
Drugs Health Pharma

Antimicrobial resistance may kill 39.1 million people by 2050: GRAM

Antibiotic-resistant infections may kill 39.1 million people in the next 25 years equating to three deaths a minute, a global study finds.

Read More
The first dosing in a late-stage trial to evaluate an investigational drug for tuberculosis (TB) has started in South Africa, which has one of the highest burdens in the world.
Drugs Health Pharma

First late-stage trial vaccine doses begin in South Africa for tuberculosis

Ā HQ Team March 20, 2024: The first dosing in a late-stage trial to evaluate an investigational drug for tuberculosis (TB) has started in.

Read More
Researchers at the University of Cambridge have moved away from cells of zebrafish and mice to create a ā€œhuman embryo-like modelā€ from human cells to predict early-stage pregnancy failures.
Drugs Health Pharma

Human embryo model to predict early stage pregnancy failure

Researchers at the University of Cambridge have moved away from cells of zebrafish and mice to create a ā€œhuman embryo-like modelā€ from human.

Read More
Drugs Medical Pharma

Wellcome, Bill & Melinda invest $550 million for new TB vaccine

HQ Team June 30, 2023: Two philanthropic health majors, Wellcome and the Bill & Melinda Gates Foundation, have come together to invest around.

Read More
Cholera oral vacccine
Drugs Health Medical Pharma

Biovac signs deal for oral cholera vaccine with S.Korea’s IVI

Biovac, a South Africa-based biotechnology company, has signed a technology transfer agreement with a South Korean institute to make an oral cholera vaccine.

Read More